Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.46 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2147650 | 0.87 | KMT2A (0.65) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL9844053 | 0.86 | KMT2A (0.50) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL9843942 | 0.85 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL9844301 | 0.82 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL9843954 | 0.79 | SOAT1 (0.47) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL6899771 | 0.74 | SOAT1 (0.62) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL856614 | 0.73 | KMT2A (0.40) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9843936 | 0.72 | SMN1; SMN2 (0.77) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL9844078 | 0.70 | SOAT1 (0.56) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 | |
| SCHEMBL9844128 | 0.69 | SOAT1 (0.55) | MEN1KMT2ASMN1; SMN2SOAT1SOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | claimed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | claimed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | claimed |
| EP-1673077-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MALONAMIDE DERIVATIVES FOR DECREASING SEBUM PRODUCTION | WARNER LAMBERT CO (US) | 2008-10-01 | — | — | EP | claimed |
| EP-1673077-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MALONAMIDE DERIVATIVES FOR DECREASING SEBUM PRODUCTION | WARNER-LAMBERT COMPANY (US) | 2006-06-28 | — | — | EP | claimed |
| WO-2005034931-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MALONAMIDE DERIVATIVES FOR DECREASING SEBUM PRODUCTION | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-21 | — | — | WO | claimed |
| US-20050079144-A1 | Method for decreasing sebum production | BAUSCH & LOMB MEXICO, S.A. DE C.V. (MX) | 2005-04-14 | — | — | US | claimed |
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | claimed |
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-7615230-B2 | Topical applying N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide as ACAT inhibitor to treat oily skin; acylcoenzyme a cholesterol acyltransferase (ACAT) | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-10 | — | — | US | disclosed |
| EP-1673077-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MALONAMIDE DERIVATIVES FOR DECREASING SEBUM PRODUCTION | WARNER LAMBERT CO (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1673077-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MALONAMIDE DERIVATIVES FOR DECREASING SEBUM PRODUCTION | WARNER-LAMBERT COMPANY (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005034931-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MALONAMIDE DERIVATIVES FOR DECREASING SEBUM PRODUCTION | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050079144-A1 | Method for decreasing sebum production | BAUSCH & LOMB MEXICO, S.A. DE C.V. (MX) | 2005-04-14 | — | — | US | disclosed |
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | MEN1 2206/4885KMT2A 2011/4885SMN1; SMN2 4663/4885 |
| US-20050079144-A1 | Method for decreasing sebum production | ACAT2, ACAT1, ACOT7 | MEN1 2206/4885KMT2A 2011/4885SMN1; SMN2 4663/4885 |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | MEN1 2206/4885KMT2A 2011/4885SMN1; SMN2 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.